Sexually Transmitted Diseases (STD) Treatment Market Size, Share, and Outlook, H2-2025 Report- By Disease (Gonorrhea, Syphilis, Herpes, Chlamydia, Hepatitis (HBV), Human Immunodeficiency Virus (HIV), Others), By Therapy (Anti-bacterial, Anti-viral, Vaccin
Description
Sexually Transmitted Diseases (STD) Treatment Market Outlook
The global Sexually Transmitted Diseases (STD) Treatment Market Size is valued at $58.6 Billion in 2025 and is forecast to reach $80.8 Billion in 2032 at a CAGR of 4.7%.
The Sexually Transmitted Diseases (STD) Treatment Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Sexually Transmitted Diseases (STD) Treatment Market segments across 22 countries from 2021 to 2032. Key segments covered include By Disease (Gonorrhea, Syphilis, Herpes, Chlamydia, Hepatitis (HBV), Human Immunodeficiency Virus (HIV), Others), By Therapy (Anti-bacterial, Anti-viral, Vaccines, Anti-fungal), By Route of Administration (Oral, Injectable, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Sexually Transmitted Diseases (STD) Treatment Market Insights, 2025
The STD treatment market is marked by ongoing efforts to address rising antibiotic resistance and the need for effective therapeutic regimens for a broad spectrum of infections. Recent advancements include the development of next-generation antibiotics targeting resistant gonorrhea strains and novel antivirals for herpes simplex virus (HSV) and human papillomavirus (HPV). Combination therapies are being explored to improve efficacy and reduce treatment duration. The market is influenced by evolving clinical guidelines emphasizing personalized treatment based on resistance patterns and patient history. Injectable and long-acting formulations aim to improve adherence and reduce transmission risk. Behavioral and educational interventions are integrated with pharmacotherapy to enhance outcomes. Regulatory approvals have streamlined pathways for drugs targeting neglected STDs and emerging infections. Increasing investment in vaccine research, such as for HSV and chlamydia, also impacts therapeutic landscapes. Market growth is supported by public health initiatives and global efforts to reduce STD incidence.
Five Trends Shaping the Global Sexually Transmitted Diseases (STD) Treatment Market in 2025 and Beyond
The global Sexually Transmitted Diseases (STD) Treatment Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Sexually Transmitted Diseases (STD) Treatment Industry?
The Sexually Transmitted Diseases (STD) Treatment Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Sexually Transmitted Diseases (STD) Treatment Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Sexually Transmitted Diseases (STD) Treatment Market Segment Insights
The Sexually Transmitted Diseases (STD) Treatment Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Disease (Gonorrhea, Syphilis, Herpes, Chlamydia, Hepatitis (HBV), Human Immunodeficiency Virus (HIV), Others), By Therapy (Anti-bacterial, Anti-viral, Vaccines, Anti-fungal), By Route of Administration (Oral, Injectable, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Sexually Transmitted Diseases (STD) Treatment Industry Value Chain
The chapter identifies potential companies and their operations across the global Sexually Transmitted Diseases (STD) Treatment Industry ecosystem. It assists decision-makers in evaluating global Sexually Transmitted Diseases (STD) Treatment Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Sexually Transmitted Diseases (STD) Treatment Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Sexually Transmitted Diseases (STD) Treatment Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Sexually Transmitted Diseases (STD) Treatment Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Sexually Transmitted Diseases (STD) Treatment Market.
Europe Sexually Transmitted Diseases (STD) Treatment Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Sexually Transmitted Diseases (STD) Treatment Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Sexually Transmitted Diseases (STD) Treatment Industry competitiveness. The report analyses the key Sexually Transmitted Diseases (STD) Treatment Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Sexually Transmitted Diseases (STD) Treatment Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Sexually Transmitted Diseases (STD) Treatment Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Sexually Transmitted Diseases (STD) Treatment Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Sexually Transmitted Diseases (STD) Treatment Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Sexually Transmitted Diseases (STD) Treatment Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AbbVie Inc, Affymetrix, Aurobindo Pharma Ltd, Becton, Dickinson and Company, Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Cepheid Inc, DiaSorin SpA, Dynavax Technologies Corp, F. Hoffmann La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Hologic Inc, Inovio Pharmaceuticals Inc, Johnson and Johnson, Lee's Pharmaceutical Holdings Ltd, Lupin Ltd, Merck and Co. Inc, Mylan N.V, Pfizer Inc. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Sexually Transmitted Diseases (STD) Treatment Market Scope
Leading Segments
By Disease
Gonorrhea
Syphilis
Herpes
Chlamydia
Hepatitis (HBV)
Human Immunodeficiency Virus (HIV)
Others
By Therapy
Anti-bacterial
Anti-viral
Vaccines
Anti-fungal
By Route of Administration
Oral
Injectable
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Leading Companies
AbbVie Inc
Affymetrix
Aurobindo Pharma Ltd
Becton, Dickinson and Company
Bristol Myers Squibb Co.
C. H. Boehringer Sohn AG and Co. KG
Cepheid Inc
DiaSorin SpA
Dynavax Technologies Corp
F. Hoffmann La Roche Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Hologic Inc
Inovio Pharmaceuticals Inc
Johnson and Johnson
Lee's Pharmaceutical Holdings Ltd
Lupin Ltd
Merck and Co. Inc
Mylan N.V
Pfizer Inc
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Sexually Transmitted Diseases (STD) Treatment Market Size is valued at $58.6 Billion in 2025 and is forecast to reach $80.8 Billion in 2032 at a CAGR of 4.7%.
The Sexually Transmitted Diseases (STD) Treatment Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Sexually Transmitted Diseases (STD) Treatment Market segments across 22 countries from 2021 to 2032. Key segments covered include By Disease (Gonorrhea, Syphilis, Herpes, Chlamydia, Hepatitis (HBV), Human Immunodeficiency Virus (HIV), Others), By Therapy (Anti-bacterial, Anti-viral, Vaccines, Anti-fungal), By Route of Administration (Oral, Injectable, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Sexually Transmitted Diseases (STD) Treatment Market Insights, 2025
The STD treatment market is marked by ongoing efforts to address rising antibiotic resistance and the need for effective therapeutic regimens for a broad spectrum of infections. Recent advancements include the development of next-generation antibiotics targeting resistant gonorrhea strains and novel antivirals for herpes simplex virus (HSV) and human papillomavirus (HPV). Combination therapies are being explored to improve efficacy and reduce treatment duration. The market is influenced by evolving clinical guidelines emphasizing personalized treatment based on resistance patterns and patient history. Injectable and long-acting formulations aim to improve adherence and reduce transmission risk. Behavioral and educational interventions are integrated with pharmacotherapy to enhance outcomes. Regulatory approvals have streamlined pathways for drugs targeting neglected STDs and emerging infections. Increasing investment in vaccine research, such as for HSV and chlamydia, also impacts therapeutic landscapes. Market growth is supported by public health initiatives and global efforts to reduce STD incidence.
Five Trends Shaping the Global Sexually Transmitted Diseases (STD) Treatment Market in 2025 and Beyond
The global Sexually Transmitted Diseases (STD) Treatment Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Sexually Transmitted Diseases (STD) Treatment Industry?
The Sexually Transmitted Diseases (STD) Treatment Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Sexually Transmitted Diseases (STD) Treatment Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Sexually Transmitted Diseases (STD) Treatment Market Segment Insights
The Sexually Transmitted Diseases (STD) Treatment Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Disease (Gonorrhea, Syphilis, Herpes, Chlamydia, Hepatitis (HBV), Human Immunodeficiency Virus (HIV), Others), By Therapy (Anti-bacterial, Anti-viral, Vaccines, Anti-fungal), By Route of Administration (Oral, Injectable, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Sexually Transmitted Diseases (STD) Treatment Industry Value Chain
The chapter identifies potential companies and their operations across the global Sexually Transmitted Diseases (STD) Treatment Industry ecosystem. It assists decision-makers in evaluating global Sexually Transmitted Diseases (STD) Treatment Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Sexually Transmitted Diseases (STD) Treatment Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Sexually Transmitted Diseases (STD) Treatment Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Sexually Transmitted Diseases (STD) Treatment Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Sexually Transmitted Diseases (STD) Treatment Market.
Europe Sexually Transmitted Diseases (STD) Treatment Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Sexually Transmitted Diseases (STD) Treatment Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Sexually Transmitted Diseases (STD) Treatment Industry competitiveness. The report analyses the key Sexually Transmitted Diseases (STD) Treatment Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Sexually Transmitted Diseases (STD) Treatment Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Sexually Transmitted Diseases (STD) Treatment Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Sexually Transmitted Diseases (STD) Treatment Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Sexually Transmitted Diseases (STD) Treatment Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Sexually Transmitted Diseases (STD) Treatment Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AbbVie Inc, Affymetrix, Aurobindo Pharma Ltd, Becton, Dickinson and Company, Bristol Myers Squibb Co., C. H. Boehringer Sohn AG and Co. KG, Cepheid Inc, DiaSorin SpA, Dynavax Technologies Corp, F. Hoffmann La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, Hologic Inc, Inovio Pharmaceuticals Inc, Johnson and Johnson, Lee's Pharmaceutical Holdings Ltd, Lupin Ltd, Merck and Co. Inc, Mylan N.V, Pfizer Inc. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Sexually Transmitted Diseases (STD) Treatment Market Scope
Leading Segments
By Disease
Gonorrhea
Syphilis
Herpes
Chlamydia
Hepatitis (HBV)
Human Immunodeficiency Virus (HIV)
Others
By Therapy
Anti-bacterial
Anti-viral
Vaccines
Anti-fungal
By Route of Administration
Oral
Injectable
Topical
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Leading Companies
AbbVie Inc
Affymetrix
Aurobindo Pharma Ltd
Becton, Dickinson and Company
Bristol Myers Squibb Co.
C. H. Boehringer Sohn AG and Co. KG
Cepheid Inc
DiaSorin SpA
Dynavax Technologies Corp
F. Hoffmann La Roche Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Hologic Inc
Inovio Pharmaceuticals Inc
Johnson and Johnson
Lee's Pharmaceutical Holdings Ltd
Lupin Ltd
Merck and Co. Inc
Mylan N.V
Pfizer Inc
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
187 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Sexually Transmitted Diseases (STD) Treatment Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Sexually Transmitted Diseases (STD) Treatment Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Sexually Transmitted Diseases (STD) Treatment Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Sexually Transmitted Diseases (STD) Treatment Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Sexually Transmitted Diseases (STD) Treatment Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Disease
- Gonorrhea
- Syphilis
- Herpes
- Chlamydia
- Hepatitis (HBV)
- Human Immunodeficiency Virus (HIV)
- Others
- By Therapy
- Anti-bacterial
- Anti-viral
- Vaccines
- Anti-fungal
- By Route of Administration
- Oral
- Injectable
- Topical
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6. Global Sexually Transmitted Diseases (STD) Treatment Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Sexually Transmitted Diseases (STD) Treatment Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Sexually Transmitted Diseases (STD) Treatment Market Trends and Growth Opportunities
- 6.2.1 North America Sexually Transmitted Diseases (STD) Treatment Market Outlook by Type
- 6.2.2 North America Sexually Transmitted Diseases (STD) Treatment Market Outlook by Application
- 6.3 North America Sexually Transmitted Diseases (STD) Treatment Market Outlook by Country
- 6.3.1 The US Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 6.3.2 Canada Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 6.3.3 Mexico Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7. Europe Sexually Transmitted Diseases (STD) Treatment Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Sexually Transmitted Diseases (STD) Treatment Market Trends and Growth Opportunities
- 7.2.1 Europe Sexually Transmitted Diseases (STD) Treatment Market Outlook by Type
- 7.2.2 Europe Sexually Transmitted Diseases (STD) Treatment Market Outlook by Application
- 7.3 Europe Sexually Transmitted Diseases (STD) Treatment Market Outlook by Country
- 7.3.2 Germany Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7.3.3 France Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7.3.4 The UK Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7.3.5 Spain Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7.3.6 Italy Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7.3.7 Russia Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8. Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Outlook by Type
- 8.2.2 Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Outlook by Application
- 8.3 Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Outlook by Country
- 8.3.1 China Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8.3.2 India Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8.3.3 Japan Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8.3.4 South Korea Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8.3.5 Australia Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8.3.6 South East Asia Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 9. South America Sexually Transmitted Diseases (STD) Treatment Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Sexually Transmitted Diseases (STD) Treatment Market Trends and Growth Opportunities
- 9.2.1 South America Sexually Transmitted Diseases (STD) Treatment Market Outlook by Type
- 9.2.2 South America Sexually Transmitted Diseases (STD) Treatment Market Outlook by Application
- 9.3 South America Sexually Transmitted Diseases (STD) Treatment Market Outlook by Country
- 9.3.1 Brazil Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 9.3.2 Argentina Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 10. Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Market Outlook by Type
- 10.2.2 Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Market Outlook by Application
- 10.3 Middle East and Africa Sexually Transmitted Diseases (STD) Treatment Market Outlook by Country
- 10.3.1 Saudi Arabia Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 10.3.2 The UAE Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 10.3.4 South Africa Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 10.3.5 Egypt Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Sexually Transmitted Diseases (STD) Treatment Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- AbbVie Inc
- Affymetrix
- Aurobindo Pharma Ltd
- Becton, Dickinson and Company
- Bristol Myers Squibb Co.
- C. H. Boehringer Sohn AG and Co. KG
- Cepheid Inc
- DiaSorin SpA
- Dynavax Technologies Corp
- F. Hoffmann La Roche Ltd
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Hologic Inc
- Inovio Pharmaceuticals Inc
- Johnson and Johnson
- Lee's Pharmaceutical Holdings Ltd
- Lupin Ltd
- Merck and Co. Inc
- Mylan N.V
- Pfizer Inc
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
